After 30 years of use in transplant medicine, EBV-specific T cells offer key lessons for safer, scalable allogeneic cell therapies, writes Ivan Horak, M.D.

On this weeks episode of the Business of Biotech, Cyriac Roeding talks about cofounding and leading Earli, a "bioAI" company using synthetic DNA switches and cancer-binding lipid nanoparticles to ...

Candidates for seats on company boards should scrutinize governance, culture, and leadership dynamics before saying yes, ...

On this weeks episode of the Business of Biotech, Philina Lee, Ph.D., CEO at AdvanCell, explains how lead-based targeted alpha therapies can unlock deeper, more durable cancer responses, and why ...

Servant leadership means putting people first because results follow people, not the other way around, writes Boehringer ...

A company launching a drug in the United States in 2027 will hire its contract sales organization (CSO) from a market that has changed since its executives last bought from it. Five of the best-known ...

On this week's episode of the Business of Biotech, Alex Aravanis, M.D., Ph.D., CEO of Moonwalk Biosciences, talks about the opportunity in obesity beyond GLP-1s. He describes Moonwalk’s ...

Kenneth Wu has been consulting in clinical operations for biopharmaceutical and medical device sponsors for over a decade. His professional career advanced from clinical research associate (CRA) to ...

On this week's episode of the Business of Biotech, Independent Board Director and five-time public company CFO Alan Shaw returns to the show for an update on current biotech financing and the ...

In biotech, a patent strategy is rarely just about securing a filing date. It is about preserving optionality through financing, partnering, commercialization, and eventual exit. The patent estate has ...

Research Triangle Park transformed 7,000 acres of North Carolina’s “possums and pines” into the nation’s largest science park and a globally recognized center for research, technology and life ...

Private equity is often associated with aggressive cost-cutting and quick exits, but QHP Capital takes a different approach. The Raleigh-based life sciences investment firm partners with midsize, ...